Compare Advance Auto Parts, Inc. (AAP) vs Inovio Pharmaceuticals Inc (INO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Advance Auto Parts, Inc. vs Inovio Pharmaceuticals Inc — how do they compare? Advance Auto Parts, Inc. trades at $53.44 (market cap $3.19B), while Inovio Pharmaceuticals Inc trades at $0.77 (market cap $78.55M). The key difference: Advance Auto Parts, Inc. is far larger — about 40.6× Inovio Pharmaceuticals Inc's market cap, and Advance Auto Parts, Inc. pays a 1.89% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AAP | INO | |
|---|---|---|
Market Cap | $3.19B | $78.55M |
Sector | Consumer Cyclical | Health |
52-Week High | $64.17 | $2.87 |
52-Week Low | $38.75 | $0.66 |
Enterprise Value | $5.47B | $49.56M |
Dividend Yield | 1.89% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Advance Auto Parts (AAP) trades at $53.59, down 3.84% on the day, with a bearish technical signal. Recent earnings have consistently beaten estimates, but profitability remains thin with a net margin of 0.51%. The company is executing a turnaround focused on professional sales and supply chain restructuring. Cash flow trends show heavy financing activity supporting operations.
The outlook is mixed; analyst consensus is a Buy with a $61.30 price target, but high debt and weak operating cash flow pose risks. Upside depends on successful execution of the restructuring plan to improve margins and stabilize revenue. Near-term support is at $52, with resistance at $55.
INO trades at $0.76, up 2.74% today, but remains in a bearish technical trend. The company shows minimal revenue of $65K against high operating losses, with a net income margin of -130,000%. Recent quarterly EPS has beaten expectations. Analyst consensus is bullish with a $3.25 price target, but the stock faces significant fundamental challenges including negative cash flow and high valuation multiples.
The outlook hinges on FDA approval of INO-3107 in October 2026, a binary event that could drive substantial upside. However, persistent cash burn, negative profitability, and ongoing shareholder litigation present high risks. Investors should weigh the potential catalyst against the company's weak financial health and operational execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Advance Auto Parts, Inc.
Advance Auto Parts is one of the industry's largest retailers of aftermarket automotive parts, tools, and accessories to do-it-yourself customers in North America. Advance operated 4,972 stores as of the end of 2021, in addition to servicing 1,317 independently owned Carquest stores. The company's Worldpac unit is a premier distributor of imported original-equipment parts. Advance derived 58% of its 2021 sales from commercial clients, up from 30%-40% before the General Parts deal.
Read more on AAP →About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →
